Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer
Loading...
Date
Authors
Rapoport, Bernardo Leon
Arani, Ramin B.
Mathieson, Nicola
Krendyukov, Andriy
Journal Title
Journal ISSN
Volume Title
Publisher
Future Medicine
Abstract
AIM : This meta-analysis compared incidence of grade 3-4 neutropenia with ALK inhibitors versus chemotherapy in patients with non-small-cell lung cancer. MATERIALS AND METHODS : PubMed/MEDLINE was searched to identify Phase II and III randomized clinical trials published up to 25 October 2018. Summary incidence, relative risk and corresponding 95% CIs were calculated for grade 3-4 neutropenia. RESULTS : Five randomized clinical trials were included. Relative risk (95% CI) of developing grade 3-4 neutropenia with ALK inhibitor versus chemotherapy was 0.27 (0.07-1.06). Probabilities of developing grade 3-4 neutropenia were 6.56 and 14.19%, respectively; no significant difference was found. CONCLUSION : In patients with non-small-cell lung cancer, incidence of grade 3-4 neutropenia with ALK-targeted therapy is not significantly different compared with chemotherapy.
Description
Keywords
Alectinib, ALK inhibitor, Anaplastic lymphoma kinase, Ceritinib, Chemotherapy, Crizotinib, Neutropenia, Non-small-cell lung cancer, Targeted therapy, Non-small-cell lung carcinoma (NSCLC), Anaplastic lymphoma kinase (ALK)
Sustainable Development Goals
Citation
Rapoport, B., Arani, R.B., Mathieson, N. et al. 2019, 'Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer', Future Oncology, vol. 15, no. 18, pp. 2163-2174.